Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Dysregulated metabolism: a relevant player in prostate cancer progression and clinical management.

Ferro M, Buonerba C, Di Lorenzo G, de Cobelli O, Terracciano D.

Transl Androl Urol. 2019 Mar;8(Suppl 1):S109-S111. doi: 10.21037/tau.2018.12.05. No abstract available.


Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.

Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC.

Cancer Res. 2004 Mar 15;64(6):2212-21.


The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.

Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA.

Cancer Metab. 2016 Dec 7;4:22. doi: 10.1186/s40170-016-0161-9. eCollection 2016.


The Metabolic Landscape of Prostate Cancer.

Giunchi F, Fiorentino M, Loda M.

Eur Urol Oncol. 2019 Feb;2(1):28-36. doi: 10.1016/j.euo.2018.06.010. Epub 2018 Jul 19. Review.


A networks method for ranking microRNA dysregulation in cancer.

Budd WT, Seashols S, Weaver D, Joseph C, Zehner ZE.

BMC Syst Biol. 2013;7 Suppl 5:S3. doi: 10.1186/1752-0509-7-S5-S3. Epub 2013 Dec 9.


Reprint of: The prostate cancer genome: Perspectives and potential.

Barbieri CE, Tomlins SA.

Urol Oncol. 2015 Feb;33(2):95-102. doi: 10.1016/j.urolonc.2015.01.002. Review.


eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.

Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14134-9. doi: 10.1073/pnas.1005320107. Epub 2010 Aug 2.


Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy.

Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y.

Cancer Med. 2018 Dec;7(12):6124-6136. doi: 10.1002/cam4.1820. Epub 2018 Nov 6. Review.


Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Voelkel-Johnson C, Norris JS, White-Gilbertson S.

Adv Cancer Res. 2018;140:265-293. doi: 10.1016/bs.acr.2018.04.014. Epub 2018 Jun 20.


Emerging role of microRNAs in prostate cancer: implications for personalized medicine.

Gandellini P, Folini M, Zaffaroni N.

Discov Med. 2010 Mar;9(46):212-8. Review.


CK2 signaling in androgen-dependent and -independent prostate cancer.

Wang G, Ahmad KA, Unger G, Slaton JW, Ahmed K.

J Cell Biochem. 2006 Oct 1;99(2):382-91. Review.


Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis?

Krycer JR, Brown AJ.

PLoS One. 2013;8(1):e54007. doi: 10.1371/journal.pone.0054007. Epub 2013 Jan 8.


The prostate cancer genome: perspectives and potential.

Barbieri CE, Tomlins SA.

Urol Oncol. 2014 Jan;32(1):53.e15-22. doi: 10.1016/j.urolonc.2013.08.025. Epub 2013 Nov 13. Review.


Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression.

Li Y, Vongsangnak W, Chen L, Shen B.

BMC Med Genomics. 2014;7 Suppl 1:S3. doi: 10.1186/1755-8794-7-S1-S3. Epub 2014 May 8.


The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H.

Clin Cancer Res. 2018 Feb 15;24(4):927-938. doi: 10.1158/1078-0432.CCR-17-0989. Epub 2017 Nov 20.


Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R; REDEEM Study Group.

Contemp Clin Trials. 2007 Nov;28(6):763-9. Epub 2007 May 29.


Steroid hormone synthetic pathways in prostate cancer.

Mostaghel EA.

Transl Androl Urol. 2013 Sep;2(3):212-227.


Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.

Li J, Ren S, Piao HL, Wang F, Yin P, Xu C, Lu X, Ye G, Shao Y, Yan M, Zhao X, Sun Y, Xu G.

Sci Rep. 2016 Feb 11;6:20984. doi: 10.1038/srep20984.


Reps2: a cellular signaling and molecular trafficking nexus.

Badway JA, Baleja JD.

Int J Biochem Cell Biol. 2011 Dec;43(12):1660-3. doi: 10.1016/j.biocel.2011.08.014. Epub 2011 Sep 3. Review.


The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.

Bishop JL, Thaper D, Zoubeidi A.

Cancers (Basel). 2014 Apr 9;6(2):829-59. doi: 10.3390/cancers6020829.

Supplemental Content

Support Center